Full-Time

Archivist Assistant

Posted on 5/9/2026

Inotiv

Inotiv

1,001-5,000 employees

Global CRO for life sciences research

No salary listed

St. Louis, MO, USA + 1 more

More locations: Dublin, OH, USA

In Person

Category
Biology & Biotech (1)
Requirements
  • Bachelor’s degree or higher (life sciences preferred)
  • One year or more of relevant industry experience
  • Equivalent combination of related education and required work experience will be considered with Management approval
  • Outstanding organizational skills
  • An aptitude for quality and an eye for detail
  • Ability to work independently or as a team member
  • Ability to follow written instructions and work with a minimum of supervision
  • Proficient in applicable computer applications including MS Office
  • Ability to understand scientific protocols and reports
Responsibilities
  • Follow SOPs and other applicable laboratory or company procedures - Maintain confidential information consistent with Inotiv corporate policy
  • Demonstrate Inotiv Core Values General
  • Interact with clients, other employees, and the community in a professional manner
  • Support and participate in company initiatives
  • Maintain thorough knowledge of facility SOPs, policies, study protocols, etc. Adhere to all safety regulations and procedures - Perform other duties as assigned Specific
  • Collaborate with team members to accomplish group activities in a time-sensitive manner
  • Update and keep information current in archive management and project management software.
  • Receive and file data and materials provided by clients or other Inotiv sites as applicable
  • Prepare data, specimens, reports, protocols, etc. for archival as applicable and organize and scan data packages
  • Work with Shipping/Receiving personnel and/or the Archivist to ensure reports and study materials are returned to the client or archived as directed
  • Monitor access to the Temporary Retention Area

Inotiv provides contract research services across drug discovery, preclinical testing, analytical testing, and related areas for the pharmaceutical and biotech industries. Its offerings combine analytical chemistry, preclinical research, and access to a broad set of research models to generate data and prepare regulatory-compliant documentation that supports drug development, safety testing, and medical device evaluation. The company differentiates itself through an integrated CRO model that pairs BASi’s analytical capabilities, Seventh Wave’s preclinical work, and Envigo’s research models in one end-to-end service. Its goal is to be a global partner for drug discovery, safety assessment, and product development by delivering scalable research services and regulatory-grade data to biopharma and medical device customers.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

West Lafayette, Indiana

Founded

1974

Simplify Jobs

Simplify's Take

What believers are saying

  • Ranked 182nd on 2025 Deloitte Technology Fast 500 with 448% growth.
  • FY2025 revenue reached $513.0M with $138M DSA backlog.
  • Raised $27.6M via equity offerings in December 2024 for expansion.

What critics are saying

  • Qilin ransomware attack in August 2025 disrupts operations and data.
  • $11M Animal Welfare Act fine for beagle mistreatment triggers USDA scrutiny.
  • FDA prioritizes non-animal testing, slashing demand for animal models.

What makes Inotiv unique

  • BASi merged with Seventh Wave in 2018, combining analytical and preclinical expertise.
  • Acquired Envigo in November 2021, expanding research models and services.
  • Partners with VUGENE on December 11, 2025, integrating AI-driven bioinformatics.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Inotiv who can refer or advise you

Benefits

Health Insurance

Pension

Life Insurance

Wellbeing Program

Paid Time Off

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Stock Options

Company Equity

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Parental Leave

Paid Holidays

Short-term Disability

Long-term Disability

Dental Insurance

Vision Insurance

Phone/Internet Stipend

Home Office Stipend

Paid Vacation

Paid Sick Leave

Flexible Benefits Scheme

Employee Assistance Program

Private Health Insurance

Health cash plan

Retail discounts

Education allowance

Tuition Reimbursement

Meal Benefits

Adoption Assistance

Company News

Stock Titan
Dec 11th, 2025
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

Inotiv partners with VUGENE to advance ai-driven drug Discovery and bioinformatics capabilities. Rhea-AI summary. Inotiv (NASDAQ: NOTV) announced a strategic collaboration with VUGENE on December 11, 2025 to integrate VUGENE's cloud-based AI/ML multi-omics bioinformatics platform into Inotiv's Discovery & Translational Sciences Division. The partnership aims to accelerate AI-assisted drug discovery by improving interpretation of epigenomic, proteomic, and other molecular datasets to better predict drug efficacy and safety in early-stage research. Inotiv said the integration will enable more efficient, data-driven decision making for client discovery programs, while VUGENE expects broader application of its computational technologies in real-world research settings. News market reaction 1 alert. On the day this news was published, NOTV declined 4.48%, reflecting a moderate negative market reaction. Data tracked by StockTitan Argus on the day of publication. Technical Shares at 0.8414 are trading below the 200-day MA of 1.87 and 87.02% under the 52-week high. Peers on Argus 1 down. Sector peers show mixed moves, with ADVB down 9.61% and others modestly up or down. With only one peer in momentum and no shared news, the AI-focused partnership appears company-specific rather than part of a sector-wide move. Historical context. | Date | Event | Sentiment | Move | Catalyst | | Dec 03 | Earnings report | Positive | +8.1% | Reported FY2025 revenue growth and sharply reduced operating loss. | | Nov 25 | Growth ranking | Positive | +3.9% | Ranked 182nd on Deloitte Technology Fast 500 with 448% growth. | | Nov 21 | Earnings date notice | Neutral | -3.9% | Announced timing and access details for FY2025 results call. | | Nov 17 | Preliminary results | Positive | -33.2% | Shared preliminary FY2025 revenue and strong DSA growth metrics. | | Oct 21 | Conference participation | Neutral | -2.2% | Outlined participation in multiple November investor conferences. | Operationally positive news has sometimes aligned with gains but also seen sharp selloffs, indicating inconsistent market confidence in updates. Over the last few months, Inotiv reported improving FY2025 results with Q4 revenue of $138.1M and FY revenue of $513.0M, alongside a narrowed operating loss of $30.9M. Recognition on the 2025 Deloitte Technology Fast 500(TM) and strong DSA growth, with backlog around $138M, highlight expansion. However, preliminary results on Nov 17, 2025 coincided with a -33.2% move, contrasting with the later earnings-day gain of 8.13%. Today's AI partnership adds to a pattern of strategic initiatives amid volatile reactions. Regulatory & risk context. An effective S-3 shelf filed on 2025-08-29 allows future securities offerings, including an at-the-market equity program with up to 3.0% commission. The filing highlights an auditor's explanatory paragraph raising substantial doubt about going-concern status, material weaknesses in internal control, and warns of immediate dilution risk and variable ATM proceeds. Market pulse summary. This announcement details a strategic collaboration integrating VUGENE's AI-enabled bioinformatics platform into Inotiv's Discovery & Translational Sciences Division to better analyze complex epigenomic and proteomic data. It follows FY2025 revenue of $513.0M and recognition in the 2025 Deloitte Technology Fast 500(TM). Regulatory filings, including the 2025-08-29 S-3, highlight going-concern language, internal-control weaknesses, and dilution risk. Investors may watch how this AI partnership translates into Discovery and Safety Assessment growth and backlog trends.

Stock Titan
Dec 23rd, 2024
Inotiv Raises $24M in Equity Offering

Inotiv completed an equity offering, raising approximately $24 million by selling 6 million common shares at $4.25 each. The offering closed on December 19, 2024, with Lake Street Capital Markets as the sole book-running manager. An option allows underwriters to purchase up to 900,000 additional shares until January 17, 2025. The funds will be used for working capital, capital expenditures, and general corporate purposes to enhance financial flexibility and support strategic initiatives.

GlobeNewswire
Dec 18th, 2024
Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares

WEST LAFAYETTE, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization...

CSIMarket
Dec 15th, 2024
Inotiv Inc. Raises $3.6M Equity Funding

Inotiv, Inc. raised $3.6 million through an equity offering of 900,000 shares at $4.25 each, following a previous offering that raised $24 million. The total $27.6 million will support its development and expansion efforts. Despite a current share price of $4.22, slightly below the offering price, Inotiv's stock has risen 32.54% over the past year, reflecting investor confidence. The capital injection aims to enhance Inotiv's market position in drug discovery and development services.

GlobeNewswire
Sep 16th, 2024
Inotiv, Inc. Amends Its Credit Agreement and Secures Additional Liquidity

WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research...